-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Search results for: “patient perspective”
-
US FDA Announces Multiple Moves with Implications for Lung Cancer Care
At the end of 2023, the agency approved repotrectinib for ROS1+ NSCLC, granted priority review for tarlatamab for advanced SCLC, and asked for an additional confirmatory trial for sotorasib for KRAS G12C-mutated NSCLC.
-
Patient Advocacy in 2023: A Look Back at Advocacy Efforts, Patient Concerns
Patient research advocate Angus Pratt reflects on the past year of advocacy coverage in ILCN and how the movement has evolved in recent years.
-
Patient Perspective: Patients With EGFR+ NSCLC May Still Opt for Quality Over Quantity After FLAURA2
In light of recent data from the study of osimertinib with or without chemotherapy, patient advocate Ivy Elkins said the results may sway some to add chemo to their first-line treatment plan. However, for others, the impact on quality of life will not be worth it.
-
WCLC Plenary Session Featured Lectureship Award Winners Discussing Range of Issues in Thoracic Oncology
Drs. Wendy Cooper, Melissa Culligan, And Navneet Singh concluded the session with talks on the future of pathology, enhancing the patient experience, and accurate staging in lung cancer.
-
Lectureship Award Winners Discuss Range of Issues in Thoracic Oncology During WCLC Plenary Session
Drs. Silvia Novello, Alan Sihoe, and D. Ross Camidge kicked off the session with forward-looking talks on tobacco control and smoking cessation, surgery, and medical oncology.
-
Opening Plenary Session Examines Treatment Inequities, Humanitarian Toll of Lung Cancer
In addition to thought-provoking keynotes from Her Royal Highness Princess Dina Mired and Dr. Gary Rodin, the official kickoff of #WCLC23 included a lively celebration of the meeting’s host city.
-
Presidential Symposium to Highlight Late-Breaking, Practice-Changing Research
The symposium also marks a change in IASLC leadership as Dr. Heather Wakelee will deliver the final Presidential Address of her term.
-
Session to Explore Unmet Patient Needs, Opportunities in Lung Cancer
On Sunday eight investigators—including Dr. Anne-Marie Baird and the Go2 Foundation’s Brittney Nichols, MPH—will present research on global challenges in lung cancer care during the “Barriers and Benefits” mini oral abstract session.
-
STARS Program Trains Patients, Caregivers to be Research Advocates
Each year, IASLC’s Supportive Training for Advocates on Research & Science program equips a new cohort with the skills needed to participate in thoracic oncology research.
-
See you in Singapore for the 2023 World Conference on Lung Cancer
IASLC President Dr. Heather Wakelee discusses what WCLC—this year and every year—offers the thoracic oncology community.
View ILCN Archives
Provider Resources
Popular Articles